1339 ET - Hims & Hers Health is in the midst of another big spending year that's putting pressure on its margins, but the investments should become long-term differentiators for the telehealth company, BofA Securities analysts say in a note. The analysts say they are particularly optimistic about the investments Hims & Hers is making in verticalizing its supply chain and scaling internationally. "HIMS' investments in these areas position the company to exploit the peptide opportunity (to the extent they are able to) and become a global platform of choice for large pharma," the analysts say. However, in the near-term, Wall Street's estimates look too high, the analysts say, backing their neutral rating on the stock and lowering their price target to $30 from $32, pointing in part to execution risks related to the investments. Hims & Hers Health slides nearly 14%.(kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

May 12, 2026 13:39 ET (17:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.